| Identification | Back Directory | [Name]
N1,N2-Bis[[4-(2-pyridinyl)phenyl]methyl]- 1,2-ethanediamine | [CAS]
1507370-20-8 | [Synonyms]
BC-1215
BC-1215
(BC 1215
BC-1215 >=98% (HPLC)
N1,N2-Bis[[4-(2-pyridinyl)phenyl]methyl]- 1,2-ethanediamine
1,2-Ethanediamine, N1,N2-bis[[4-(2-pyridinyl)phenyl]methyl]- | [Molecular Formula]
C26H26N4 | [MOL File]
1507370-20-8.mol | [Molecular Weight]
394.51 |
| Chemical Properties | Back Directory | [Boiling point ]
589.9±50.0 °C(Predicted) | [density ]
1.125±0.06 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Sealed in dry,2-8°C | [solubility ]
DMSO: soluble2mg/mL, clear (warmed) | [form ]
A crystalline solid | [pka]
9.05±0.20(Predicted) | [color ]
white to beige | [InChI]
InChI=1S/C26H26N4/c1-3-15-29-25(5-1)23-11-7-21(8-12-23)19-27-17-18-28-20-22-9-13-24(14-10-22)26-6-2-4-16-30-26/h1-16,27-28H,17-20H2 | [InChIKey]
IXEPQJQQSLMESJ-UHFFFAOYSA-N | [SMILES]
C(NCC1=CC=C(C2=NC=CC=C2)C=C1)CNCC1=CC=C(C2=NC=CC=C2)C=C1 |
| Hazard Information | Back Directory | [Description]
BC-1215 (N1,N2-Bis[[4-(2-pyridinyl)phenyl]methyl]- 1,2-ethanediamine) is an inhibitor of F-box protein 3 (FBXO3; IC50 = 0.9 μg/mL for Il-1β release). It decreases FBXO3 interaction with F-box/LRR-repeat protein 2 (FBXL2) in a dose-dependent manner and prevents FBXO3-dependent ubiquitination of FBXL2. It also lowers expression of Tnf receptor-associated factors (TRAFs) 1-6 without affecting TRAF1-6 mRNA levels in resting and LPS-stimulated peripheral blood mononuclear cells (PBMCs). BC-1215 (100 μg, i.p., per animal) reduces plasma levels of the inflammatory cytokines Il-6, Tnf, and Il-1β and decreases peritoneal bacteria counts in a mouse model of cecal ligation and puncture-induced sepsis. It also reduces inflammation in mouse models of DSS-induced colitis, paw edema, and ear edema. | [Uses]
BC-1215 is a F-box protein 3 (Fbxo3) inhibitor. BC-1215 works by antagonizing of Fbxo3 on TRAF cytokine signaling and exhibits a low IC50 in vitro. BC-1215 can be used for the research of inflammation[1]. | [in vivo]
BC-1215 (i.p.; 100 μg) reduces bacterial-induced inflammationa[1]. | Animal Model: | Cecal ligation and puncture (CLP)-induced sepsis model[1] | | Dosage: | 100 μg | | Administration: | i.p. | | Result: | Significantly attenuated CLP-induced secretion of all three circulating pro-inflammatory cytokines and decreased bacterial counts in the CLP model. |
| [IC 50]
Fbxo3 | [storage]
Store at -20°C | [References]
[1] Chen BB, et al. A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulateinflammation. Nat Immunol. 2013 May;14(5):470-9. DOI:10.1038/ni.2565 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|